<SEC-DOCUMENT>0001193125-16-614789.txt : 20160607
<SEC-HEADER>0001193125-16-614789.hdr.sgml : 20160607
<ACCEPTANCE-DATETIME>20160607092601
ACCESSION NUMBER:		0001193125-16-614789
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160601
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160607
DATE AS OF CHANGE:		20160607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		161700108

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d192660d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June&nbsp;1, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>0-26642</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>87-0494517</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, Utah 84108 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;584-3600 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;1, 2016, the Board of Directors of Myriad Genetics, Inc.
(&#145;Myriad&#148; or the &#147;Company&#148;) authorized an additional $200 million stock repurchase program which the Company announced on June&nbsp;7, 2016 attached hereto as Exhibit 99.1. The press release is hereby incorporated by reference
into this Item&nbsp;8.01 of this Current Report on Form 8-K and is being filed pursuant to Item&nbsp;8.01. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately
negotiated transactions as determined by the Company&#146;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other
factors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENT AND EXHIBITS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Press release dated June&nbsp;7, 2016.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MYRIAD GENETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June&nbsp;7, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ R. Bryan Riggsbee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R. Bryan Riggsbee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT INDEX </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Press release dated June&nbsp;7, 2016.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d192660dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g192660g72v02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Media Contact:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Rogers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Investor Contact:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Scott Gleason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(908) 285-0248</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(801) 584-1143</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>rrogers@myriad.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>sgleason@myriad.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Myriad Board Approves $200 Million Increase in Share Repurchase Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SALT LAKE CITY, Utah, June&nbsp;7, 2016</B> &#150; Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that its board of directors has
approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Company had repurchased greater than $1.1 billion of stock since the inception of the program in 2010 at
an average share price of $26.16. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Our priorities for capital deployment remain the same, first, internal research and development,
followed by acquisitions, and lastly, share repurchases,&#148; said Bryan Riggsbee, chief financial officer. &#147;We will continue to opportunistically repurchase shares at valuation thresholds that we believe do not reflect the inherent value of
the Company and as we look to deploy our capital most effectively to maximize shareholder returns over the long-term.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Repurchases
under Myriad&#146;s share repurchase program are made via open market or privately negotiated purchases as determined by the Company&#146;s management. The amount and timing of stock repurchases will depend on business and market conditions, stock
price, trading restrictions, acquisition activity, and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Myriad Genetics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide
with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression and guide treatment decisions
across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets,
diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company&#146;s website:
<U>www.myriad.com. </U> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad, the Myriad logo, BART, BRAC<I>Analysis</I>, Colaris, Colaris AP, myPath, myRisk, Myriad
myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States
and foreign countries. MYGN-F, MYGN-G </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements relating to the amount, timing and manner of stock repurchases; the Company&#146;s priorities for capital deployment; the Company continuing to opportunistically repurchase shares at valuation thresholds that the Company believes do not
reflect the inherent value of the Company; the manner the Company deploys its capital to most effectively to maximize shareholder returns over the long-term; and the Company&#146;s strategic directives under the caption &#147;About Myriad
Genetics.&#148; These &#147;forward-looking statements&#148; are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and
adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may
decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers&#146; reimbursement
levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable
to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests
and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services
tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to
obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we
license or acquire, including but not limited to our acquisition of a healthcare clinic in Germany; risks related to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies
underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and
patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other factors discussed under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A of our Annual report on Form 10-K for the fiscal year ended June&nbsp;30, 2015, which has been
filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g192660g72v02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g192660g72v02.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^FH6,-TD4L(E4-Y<R[77V([&B2Y7847=7+6:0PS0 9H ,T &: #- !F@ S0
M9H ,T &: #- !F@ S0 9H ,T &: #- !F@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 2@ H 3(H @N+VWMU)
MEE52%+8ZG Z\5G*I".[-(TY2V1RVE2+I?C"YLXXH8K+4E^U1RR7.999#U 0]
M!73=5*:DCGLZ=5Q_JYV-9&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M74]?N?&5KJT\MG?!E%K(I!0YY!YQQCC%=]67+%4VM4<5&/-)U4]&>A5RG2%
M!0 4 % !0 4 % !0 4 <?XXL?$5ZMF-"E=%5CY@238<\8.?2FK=1._0Z>P2X
MCL8$NG#W 0"1AT+8YI#+- !0 4 % !0 &@#S?P'_ ,CMXA_WF_\ 0S52V1,=
MV>D5)0M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2VMU#+83L< 3?=)^O;\:3BT-21D^ O\ D=O$/^\W_H9IRV0H[L](J2A: "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M4>5> Y)/"'Q)O_#EPQ6"X)6//<CE#^(XKMK?O:2FNAY^'_<UG3?4]-\8:T-
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MY@/F0_6A.P-7T.&^%\,EOX@U:&;/F1Q[6SZAJJ1$3U.I+%H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M _3YJJA#V?-*70G$S]KRPCU/7=-L(=,TVVLK=0L4$81?P%<$GS.[/02459'
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MB@ Q0 8H ,4 &* #% !B@ Q0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\/>)WDE%:=W_ %_7Z>A5)1'/!#=6\MO<1)-!*I22.10RNI&""#P01VH P_\
MA!/!_P#T*FC?^ $7_P 30 ?\()X/_P"A4T;_ , (O_B: #_A!/!__0J:-_X
M1?\ Q- !_P ()X/_ .A4T;_P B_^)H /^$$\'_\ 0J:-_P" $7_Q- !_P@G@
M_P#Z%31O_ "+_P")H /^$$\'_P#0J:-_X 1?_$T '_"">#_^A4T;_P  (O\
MXF@ _P"$$\'_ /0J:-_X 1?_ !- !_P@G@__ *%31O\ P B_^)H /^$$\'_]
M"IHW_@!%_P#$T '_  @G@_\ Z%31O_ "+_XF@ _X03P?_P!"IHW_ ( 1?_$T
M '_"">#_ /H5-&_\ (O_ (F@ _X03P?_ -"IHW_@!%_\30 ?\()X/_Z%31O_
M   B_P#B: #_ (03P?\ ]"IHW_@!%_\ $T '_"">#_\ H5-&_P# "+_XF@ _
MX03P?_T*FC?^ $7_ ,30 ?\ "">#_P#H5-&_\ (O_B: #_A!/!__ $*FC?\
M@!%_\30 ?\()X/\ ^A4T;_P B_\ B: #_A!/!_\ T*FC?^ $7_Q- !_P@G@_
M_H5-&_\  "+_ .)H /\ A!/!_P#T*FC?^ $7_P 30 ?\()X/_P"A4T;_ , (
MO_B: #_A!/!__0J:-_X 1?\ Q- !_P ()X/_ .A4T;_P B_^)H /^$$\'_\
M0J:-_P" $7_Q- !_P@G@_P#Z%31O_ "+_P")H /^$$\'_P#0J:-_X 1?_$T
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M_B: #_A!/!__ $*FC?\ @!%_\30 ?\()X/\ ^A4T;_P B_\ B: #_A!/!_\
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M (F@ _X03P?_ -"IHW_@!%_\30 ?\()X/_Z%31O_   B_P#B: #_ (03P?\
M]"IHW_@!%_\ $T '_"">#_\ H5-&_P# "+_XF@ _X03P?_T*FC?^ $7_ ,30
M ?\ "">#_P#H5-&_\ (O_B: #_A!/!__ $*FC?\ @!%_\30 ?\()X/\ ^A4T
M;_P B_\ B: #_A!/!_\ T*FC?^ $7_Q- !_P@G@__H5-&_\  "+_ .)H /\
MA!/!_P#T*FC?^ $7_P 30 ?\()X/_P"A4T;_ , (O_B: #_A!/!__0J:-_X
M1?\ Q- !_P ()X/_ .A4T;_P B_^)H /^$$\'_\ 0J:-_P" $7_Q- &Y!!#:
MV\5O;Q)#!$H2..-0JHH&  !P !VH DH * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
< "@ H * "@ H * "@ H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
